NCT00191256已完成2 期
Randomized Phase II Trial to Outline the Efficacy of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/Paclitaxel) When Used as Preoperative Chemotherapy In Patients With Stage I and II NSCLC
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 77
- 试验地点
- 1
- 主要终点
- Pathological complete response rate, in previously untreated patients with clinical Stage I and II non-small cell lung cancer (NSCLC).
研究概览
简要总结
To evaluate the rate of complete pathological response after 3 cycles of gemcitabine containing chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed non small cell lung cancer
- •No prior chemotherapy or radiation for non small cell lung cancer
- •No prior malignancy
排除标准
- •Pregnancy or breastfeeding
- •Serious concomitant disorders
结局指标
主要结局
Pathological complete response rate, in previously untreated patients with clinical Stage I and II non-small cell lung cancer (NSCLC).
次要结局
- Response rate, disease free survival,toxicities including pulmonary toxicity, operative mortality, and quality of life.
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Study of Locally Advanced Pancreatic CancerLocally Advanced Pancreatic CancerNCT01063192National Health Research Institutes, Taiwan73
已完成
3 期
Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian CancerOvarian CancerNCT00102414AGO Study Group356
已完成
2 期
Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic CancerPancreatic NeoplasmNCT00267020Eli Lilly and Company130
进行中（未招募）
2 期
GABARNANCE TrialJPRN-jRCTs031180319Ikeda Masafumi110
招募中
2 期
Randomized phase II/III study of gemcitabine and nab-paclitaxel therapy versus S-1 and concurrent radiotherapy as neoadjuvant treatment for Borderline resectable pancreatic cancerBorderline Resectable Pancreatic CancerJPRN-UMIN000026858EPOC A1601/JASPAC07110